Rallybio Corp (RLYB) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rallybio Corporation on May 4, 2026, covering events occurring on May 3, 2026. The filing addresses the termination of a previously announced merger agreement with Candid Therapeutics, Inc.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The primary financial impact disclosed is a one-time termination fee.
- Termination Fee: Rallybio is entitled to receive a $50,000,000 Parent Termination Fee from Candid Therapeutics, Inc.
- Expense Reimbursement: Candid agreed to reimburse certain expenses related to the transaction.
Material Changes
The material change reported is the termination of the Agreement and Plan of Merger and Reorganization entered into on March 1, 2026. Candid terminated the agreement to pursue a Permitted Alternative Agreement with UCB S.A. Consequently, Rallybio intends to withdraw its registration statement on Form S-4 filed in March and amended in April 2026.
Outlook, Risks, and Management Commentary
Management has executed a Waiver agreement with Candid and UCB S.A. to facilitate the termination. Key terms include:
- Rallybio waived certain rights related to the Company Determination Notice and Company Notice Period.
- Payment of the termination fee and expense reimbursement is scheduled for the first business day after termination.
- Upon receipt of the fee and reimbursement, Rallybio agreed to release all claims against Candid, UCB, and their affiliates regarding the merger and its termination.
- Candid and UCB agreed to release Rallybio and its affiliates from all related claims.
The filing does not provide specific forward-looking guidance or updated risk factors beyond the immediate resolution of the merger termination.
Investor Verification Checklist
- Confirm the receipt of the $50,000,000 termination fee and expense reimbursement on the first business day following May 3, 2026.
- Verify the official withdrawal of the Form S-4 registration statement with the SEC.
- Review the full text of the Waiver (Exhibit 2.1) for any undisclosed conditions or covenants.
- Monitor for any subsequent announcements regarding Rallybio's strategic direction following the failed merger.